We have located links that may give you full text access.
Osteosarcopenia in reproductive-aged women with polycystic ovary syndrome: a multicenter case-control study.
Journal of Clinical Endocrinology and Metabolism 2020 July 3
CONTEXT: Osteosarcopenia (loss of skeletal muscle and bone mass and/or function usually associated with aging) shares pathophysiological mechanisms with polycystic ovary syndrome (PCOS). However, the relationship between osteosarcopenia and PCOS remains unclear.
OBJECTIVE: We evaluated skeletal muscle index% (SMI%=[appendicular muscle mass/weight {kg}]×100) and bone mineral density (BMD) in PCOS (hyperandrogenism+oligoamenorrhea), and contrasted these musculoskeletal markers against 3 reproductive phenotypes: (1) HA (hyperandrogenism+eumenorrhea); (2) OA (normoandrogenic+oligoamenorrhea) and, (3) controls (normoandrogenic+eumenorrhea). Endocrine predictors of SMI% and BMD were evaluated across the groups.
DESIGN, SETTING, PARTICIPANTS: Multicenter case-control study of 203 women (18-48y) in New York State.
RESULTS: PCOS group exhibited reduced SMI% (mean [95%CI]; 26.2% [25.1,27.3] vs. 28.8% [27.7,29.8]), lower-extremity SMI% (57.6% [56.7,60.0] vs. 62.5% [60.3,64.6]), and BMD (1.11 [1.08,1.14] vs. 1.17 [1.14,1.20] g/cm2) compared to controls. PCOS group also had decreased upper (0.72 [0.70,0.74] vs. 0.77 [0.75,0.79] g/cm2) and lower (1.13 [1.10,1.16] vs. 1.19 [1.16,1.22] g/cm2) limb BMD compared to HA. Matsuda index was lower in PCOS vs. controls and positively associated with SMI% in all groups (All:P≤0.05). Only controls showed associations between insulin-like-growth-factor-1 (IGF-1) and upper (r=0.84) and lower (r=0.72) limb BMD (All:P<0.01). Unlike in PCOS, IGF binding-protein-2 was associated with SMI% in controls (r=0.45) and HA (r=0.67), and with upper limb BMD (r=0.98) in HA (All:P<0.05).
CONCLUSIONS: Women with PCOS exhibit early signs of osteosarcopenia when compared to controls likely attributed to disrupted insulin function. Understanding the degree of musculoskeletal deterioration in PCOS is critical for implementing targeted interventions that prevent and delay osteosarcopenia in this clinical population.
OBJECTIVE: We evaluated skeletal muscle index% (SMI%=[appendicular muscle mass/weight {kg}]×100) and bone mineral density (BMD) in PCOS (hyperandrogenism+oligoamenorrhea), and contrasted these musculoskeletal markers against 3 reproductive phenotypes: (1) HA (hyperandrogenism+eumenorrhea); (2) OA (normoandrogenic+oligoamenorrhea) and, (3) controls (normoandrogenic+eumenorrhea). Endocrine predictors of SMI% and BMD were evaluated across the groups.
DESIGN, SETTING, PARTICIPANTS: Multicenter case-control study of 203 women (18-48y) in New York State.
RESULTS: PCOS group exhibited reduced SMI% (mean [95%CI]; 26.2% [25.1,27.3] vs. 28.8% [27.7,29.8]), lower-extremity SMI% (57.6% [56.7,60.0] vs. 62.5% [60.3,64.6]), and BMD (1.11 [1.08,1.14] vs. 1.17 [1.14,1.20] g/cm2) compared to controls. PCOS group also had decreased upper (0.72 [0.70,0.74] vs. 0.77 [0.75,0.79] g/cm2) and lower (1.13 [1.10,1.16] vs. 1.19 [1.16,1.22] g/cm2) limb BMD compared to HA. Matsuda index was lower in PCOS vs. controls and positively associated with SMI% in all groups (All:P≤0.05). Only controls showed associations between insulin-like-growth-factor-1 (IGF-1) and upper (r=0.84) and lower (r=0.72) limb BMD (All:P<0.01). Unlike in PCOS, IGF binding-protein-2 was associated with SMI% in controls (r=0.45) and HA (r=0.67), and with upper limb BMD (r=0.98) in HA (All:P<0.05).
CONCLUSIONS: Women with PCOS exhibit early signs of osteosarcopenia when compared to controls likely attributed to disrupted insulin function. Understanding the degree of musculoskeletal deterioration in PCOS is critical for implementing targeted interventions that prevent and delay osteosarcopenia in this clinical population.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices 
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app